Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 5Healthy Participants 5Breast Neoplasms 5Prostatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Venous Thromboembolism 2Solid Tumor, Adult 2Neoplasm Metastasis 2Healthy Volunteers 2Endometrial Neoplasms 2Colorectal Neoplasms 2Cardiovascular Diseases 2cMET-dysregulated Advanced Solid Tumors 1Venous Thrombosis 1TP53 Y220C Mutation 1Stroke 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rectal Neoplasms 1Pulmonary Embolism 1Prostatic Neoplasms, Castration-Resistant 1Precancerous Conditions 1Peripheral Nervous System Diseases 1Pain 1Ovarian Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Liver Cirrhosis 1Leiomyosarcoma 1

Interventions

repaglinide 1Tablets 1Rosuvastatin Calcium 1Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × TP53 Y220C Mutation × Rosuvastatin Calcium × Clear all
NCT07372625 2026-03-12

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

PMV Pharmaceuticals, Inc

Phase 1 Recruiting
14 enrolled
Other solid neoplasm

TP53 Y220C Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡